鸡卵黄抗IBD免疫球蛋白的提取与应用研究

对商品代蛋鸡进行强化免疫,获得抗鸡传染性法氏囊病琼扩效价为１：１２８－２５６的高免卵黄原液。将免疫球蛋白海酸钠提取法与蛋白质中性盐盐析分离法合并起来,用于上述卵黄原液免疫球蛋白Ｇ的提取。     

Clinical signs, histology, and CD3-positive cells before and after treatment of dogs with chronic enteropathies

Background: Histopathology is widely used for the diagnosis of inflammatory bowel disease in dogs. Variations in lesions and unavailability of uniform grading systems limit the usefulness of histologic examination.
Hypothesis: CD3 cell numbers in chronic enteropathies of dogs correlate with clinical activity of the disease and with severity of histopathologic changes.
Animals: Nineteen client-owned dogs examined because of chronic diarrhea, vomiting, or both.
Methods: Samples of duodenal and colonic mucosa were collected endoscopically before and after treatment. Dogs that responded to a hypoallergenic diet were grouped as food-responsive diarrhea dogs (FRD, n = 10). Dogs with no clinical improvement after 10 days of treatment then received prednisolone (immunosuppressive doses) and were grouped as steroid-responsive diarrhea dogs (SRD, n = 9). Histopathologic assessment with a standardized grading system was performed retrospectively on the intestinal samples. Histologic score, total number of infiltrating cells, and CD3-positive cells were counted and compared with the clinical scoring.
Results: No statistically significant difference was detected among histologic grading, total number of cells in the lamina propria, and T-cell numbers in biopsies before and after treatment in either group (FRD and SRD).
Conclusions and Clinical Importance: Currently used histopathologic grading scores, total numbers of cells, and numbers of CD3-positive cells did not allow differentiation between FRD and SRD and did not correlate with clinical response to therapy. Based on these results, new grading scores assessing other criteria than total cell numbers and CD3-positive cells should be evaluated in the future.     

表达鼠源GLP-2重组嗜酸乳杆菌的构建

嗜酸乳杆菌是一种常见的肠道益生菌。嗜酸乳杆菌及其代谢产物可以调节肠道菌群的比例,增强肠道屏障功能,调节相关免疫反应,从而维护肠道内环境稳态,在一定程度上达到了治疗IBD的作用。胰高血糖素样肽-2(glucagon-like peptide-2,GLP-2)作为一种肠道营养因子,可促进肠粘膜增殖、抑制其凋亡,从而改善肠屏障功能,促进肠吸收功能恢复。本研究将GLP-2与嗜酸乳杆菌信号肽重组连接pMG36e质粒上,通过电转化转入感受态嗜酸乳杆菌中,构成重组嗜酸乳杆菌。结果表明,重组pMG36e质粒中扩增GLP-2基因与基因库公布的一致,通过Western blot检测到重组嗜酸乳杆菌上清液中有GLP-2蛋白表达。重组嗜酸乳杆菌的成功构建,使GLP-2与嗜酸乳杆菌对IBD发挥了双重疗效,为后续研究重组益生菌应用于临床治疗IBD奠定了基础。     

紫锥菊和黄芪活性成分缓解IBD雏鸡免疫抑制性的研究

为探讨紫锥菊、黄芪对感染传染性法氏囊病(IBD)雏鸡免疫的影响,给14日龄雏鸡灌服不同浓度紫锥菊、黄芪合剂(按3∶1比例混匀),其有效成分为菊苣酸和黄芪多糖,连续灌服7 d,21日龄时给雏鸡接种传染性法氏囊病病毒(IBDV)。结果表明,应用紫锥菊、黄芪后可缓解IBDV造成法氏囊的病理损伤,增加免疫器官指数,在攻毒20 d后差异明显;用药组中球蛋白含量在攻毒后11 d升高明显,可以缓解免疫抑制,进而调节机体免疫机能,增强机体的防御功能,有利于该病的防治。     

同源相同（IBD）定位在QTL精细定位中的研究进展

综述了近年来发展较快的QTL定位新策略-同源相同(IBD)定位的原理与方法及其在QTL精细定位中的研究进展.     

4株鸡IBD活疫苗对鸡ND免疫抗体的影响

４株不同毒力鸡传染性法氏囊病（ＩＢＤ）活疫苗,分别接种３０ｄＳＰＦ公维,４ｄ后再接种鸡新城（ＮＤ）Ｌａｓｏｔａ系活疫苗,同时每组捕杀５只,观察法氏囊损伤情况,另４组用同１天的ＳＰＦ公无接种ＮＤ－Ｌａｓｏｔｑ系疫苗４天后再接种不同毒力的ＩＢＤ疫苗。试验结果表明,４株ＩＢＤ活疫苗对雏鸡法氏囊不同程度损伤,并且对ＮＤ免疫抗体产生有明显抑制作用。     

3种免疫植物多糖对法氏囊活疫苗的免疫效果的影响

将60只1日龄北京白鸡,饲养至14日龄,随机分组进行传染性法氏囊中等毒力疫苗的免疫,各组分别添加黄芪、岩藻和油菜3种植物提取的多糖成分,添加剂量为10 mg/只。26日龄进行二免,首免及二免都采用滴鼻点眼方式进行。二免后定期采血检测法氏囊中和抗体效价和外周血淋巴细胞体外转化率。结果表明:二免后2周,除了油菜多糖以外,其他2种多糖添加组的中和抗体滴度与对照组相比无显著差异;各组的淋巴细胞体外转化率显著高于对照组,表明3种植物多糖成分能促进淋巴细胞增殖,有待于进一步开发为传染性法氏囊病的免疫增强剂。     

免疫增强剂对IBD疫苗免疫雏鸡局部黏膜免疫功能的影响

分别将免疫增强剂“禽福”和“Inmunair”与鸡传染性法氏囊病（IBD）中等毒力活疫苗配合使用,检测免疫雏鸡哈德尔氏腺和盲肠扁桃体T细胞及IgA、IgM和IgG抗体生成细胞数量。泪液、气管液、胆汁、肠液中免疫球蛋白IgG、IgM、IgA含量的动态变化,结果发现,应用免疫增强剂IBD疫苗免疫雏鸡上述局部免疫组织及四种局部体液的相应各项免疫检测指标均较IBD疫苗单独免疫雏鸡不同程度地增高,表明免疫增强剂与疫苗联合应用,能显著提高疫苗免疫雏鸡眼部、呼吸道和消化道局部黏膜免疫功能;而IBD强毒攻击后,疫苗单独免疫雏鸡上述指标明显低于应用免疫增强剂的疫苗免疫雏鸡,同时。后者对IBD强毒攻击的有效抵抗力明显高于前者。     

Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds

Inflammatory colorectal polyp (ICRP), common in miniature dachshunds, presents with hematochezia, tenesmus and mucoid feces. Although an 80% response rate has been reported when treated with prednisolone and cyclosporine, effective treatment is needed for the remaining 20% of ICRP dogs. Leflunomide is an immunosuppressive drug reported as effective in several immune-mediated diseases. In the present study, we retrospectively evaluated the efficacy and adverse effects of leflunomide in 15 ICRP dogs that were refractory to treatment with prednisolone and cyclosporine. Treatment efficacy was assessed by endoscopy, clinical symptoms and rectal palpation. Adverse effects were determined by clinical symptoms and blood testing during follow-up. The leflunomide treatment response rate was 93.3%. The median dosage of leflunomide and the median response time were 3 mg/kg (range: 1.7–4.0 mg/kg) and 35 days (range: 20–119 days), respectively. Adverse effects observed included lethargy (3 dogs), anorexia (1 dog), respiratory symptoms (1 dog), leukocytopenia (2 dogs), thrombocytopenia (1 dog), anemia (1 dog) and liver enzyme elevation (8 dogs). Most of the adverse effects improved with symptomatic treatment and leflunomide discontinuation or dosage reduction. In conclusion, leflunomide treatment is effective in ICRP dogs refractory to treatment with prednisolone and cyclosporine. Because several adverse effects were observed, close monitoring is needed during leflunomide treatment follow-up.